Godavari Drugs Ltd
Incorporated in 1987, Godavari Drugs Ltd manufactures and sale of Active Pharmaceutical Ingredients and their intermediates[1]
- Market Cap ₹ 62.2 Cr.
- Current Price ₹ 82.6
- High / Low ₹ 155 / 79.0
- Stock P/E 14.2
- Book Value ₹ 57.6
- Dividend Yield 0.00 %
- ROCE 10.3 %
- ROE 10.6 %
- Face Value ₹ 10.0
Pros
- Company's working capital requirements have reduced from 14.3 days to 10.6 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of 3.44% over past five years.
- Company has a low return on equity of 12.5% over last 3 years.
- Company might be capitalizing the interest cost
- Promoter holding has decreased over last 3 years: -4.29%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
9 | 55 | 71 | 76 | 64 | 84 | 96 | 123 | 161 | 160 | 157 | 113 | |
8 | 49 | 67 | 70 | 60 | 78 | 90 | 113 | 150 | 150 | 143 | 102 | |
Operating Profit | 2 | 6 | 4 | 5 | 4 | 5 | 6 | 10 | 11 | 10 | 13 | 12 |
OPM % | 20% | 11% | 6% | 7% | 6% | 7% | 6% | 8% | 7% | 6% | 8% | 10% |
0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | |
Interest | 0 | 1 | 2 | 3 | 2 | 3 | 3 | 3 | 3 | 4 | 5 | 5 |
Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 |
Profit before tax | 1 | 5 | 2 | 3 | 1 | 2 | 2 | 6 | 7 | 5 | 7 | 6 |
Tax % | -121% | 23% | 38% | 33% | 37% | 31% | 13% | 28% | 25% | 23% | 20% | 22% |
2 | 4 | 1 | 2 | 1 | 1 | 2 | 4 | 5 | 4 | 6 | 4 | |
EPS in Rs | 2.06 | 4.85 | 1.79 | 2.40 | 1.10 | 1.61 | 2.66 | 5.48 | 6.97 | 5.03 | 7.37 | 5.82 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 8% |
5 Years: | 3% |
3 Years: | -11% |
TTM: | -28% |
Compounded Profit Growth | |
---|---|
10 Years: | 2% |
5 Years: | 17% |
3 Years: | -6% |
TTM: | -22% |
Stock Price CAGR | |
---|---|
10 Years: | 2% |
5 Years: | 19% |
3 Years: | 7% |
1 Year: | -18% |
Return on Equity | |
---|---|
10 Years: | 13% |
5 Years: | 15% |
3 Years: | 13% |
Last Year: | 11% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
Reserves | 2 | 6 | 7 | 9 | 10 | 11 | 13 | 17 | 22 | 26 | 31 | 36 |
2 | 8 | 16 | 16 | 19 | 22 | 28 | 30 | 23 | 36 | 58 | 62 | |
3 | 13 | 21 | 24 | 27 | 33 | 36 | 36 | 49 | 52 | 38 | 38 | |
Total Liabilities | 15 | 35 | 51 | 56 | 63 | 74 | 84 | 91 | 101 | 121 | 135 | 143 |
8 | 7 | 9 | 13 | 15 | 15 | 14 | 22 | 26 | 25 | 27 | 33 | |
CWIP | 0 | 0 | 1 | 0 | 1 | 2 | 9 | 1 | 0 | 9 | 18 | 30 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
7 | 27 | 41 | 43 | 47 | 57 | 61 | 68 | 75 | 87 | 90 | 81 | |
Total Assets | 15 | 35 | 51 | 56 | 63 | 74 | 84 | 91 | 101 | 121 | 135 | 143 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2 | -6 | -5 | 5 | 4 | 4 | 6 | 1 | 11 | 13 | 18 | 11 | |
-2 | -0 | -2 | -3 | -3 | -2 | -7 | -1 | -5 | -9 | -13 | -20 | |
0 | 6 | 7 | -2 | -0 | -1 | 0 | 0 | -6 | -4 | -6 | 8 | |
Net Cash Flow | -0 | 0 | 0 | 0 | 1 | -0 | -0 | 0 | 1 | 1 | -0 | -0 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 20 | 87 | 126 | 117 | 152 | 148 | 137 | 134 | 126 | 132 | 138 | 136 |
Inventory Days | 973 | 84 | 67 | 70 | 100 | 93 | 84 | 55 | 28 | 57 | 62 | 125 |
Days Payable | 179 | 79 | 108 | 124 | 171 | 171 | 144 | 112 | 121 | 132 | 96 | 128 |
Cash Conversion Cycle | 814 | 92 | 85 | 63 | 81 | 70 | 78 | 78 | 33 | 58 | 105 | 133 |
Working Capital Days | 120 | 63 | 44 | 40 | 47 | 38 | 31 | 46 | 32 | 23 | 9 | 11 |
ROCE % | 8% | 32% | 16% | 17% | 11% | 12% | 12% | 18% | 18% | 14% | 14% | 10% |
Documents
Announcements
-
Rescheduling Of 37Th Annual General Meeting (AGM) Of The Company
19h - Board meeting on Aug 13 for Q1 results; AGM rescheduled; trading window closed till Aug 15.
-
Board Meeting Intimation for Unaudited Standalone Financial Results Of The Company For The First Quarter Ended 30Th June, 2025 And Rescheduling Of 37Th Annual General Meeting (AGM) Of The Company
19h - Board meeting on Aug 13 for Q1 results; 37th AGM rescheduled; trading window closed till Aug 15.
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
15 Jul - Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended 30.06.2025
-
Closure of Trading Window
25 Jun - Trading window closed from July 1, 2025, till 48 hours after Q1 results announcement.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
31 May - Publication of Audited Financials of the Company for the Quarter and Year ended 31.03.2025 in News papers
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Business Overview:[1]
Company is in the business of Manufacturing APIs, drug intermediaries, and fine chemicals and caters to the global Life Science Industry. It has an active Loan License and Contract Manufacturing tie-ups with multinational companies for APIs and drug intermediates